The HD version of Eylea is helping deal with the challenge from ... deafness that has already cured two patients in a phase 1 ...

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Outperform ...

M.D., Ph.D., who cited results from a trial of DME patients who switched from Eylea to Eylea HD. There was more bad news last week for Eylea as Regeneron lost its bid to block Amgen’s biosimilar ...

(RTTNews) - Amgen Inc. (AMGN) reported earnings for its third quarter that increased from the same period last year and beat the Street estimates. The company's bottom line came in at $2.83 ...

In addition to Pfizer, Viking Therapeutics (VKTX), Roche, and Amgen, are all now developing weight loss meds. Novo Nordisk and Eli Lilly are also working on developing their own next-gen weight ...

The best 4K Blu-ray players deliver the ultimate picture quality for watching movies and TV series at home. Although streaming services are popular, Blu-rays deliver video at a higher bitrate ...

Many major companies completed stock splits this year, making it easier for a broader range of investors to access the shares. These two healthcare players could benefit from launching a split.